Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First US Lucentis Biosimilar Expected By Year End, Roche Confirms

Samsung Bioepis’ SB11 Biosimilar Pending With FDA

Executive Summary

Another of Roche’s biologic blockbusters is due to bite the dust this year, the originator has confirmed, with biosimilar competition to Lucentis forecast in the second half of 2021.

You may also be interested in...



Roche Battered By Biosimilars But Holds On To Initial Forecast

Roche insisted that “biosimilar competition is only one factor in the overall picture,” as it reported another set of depleted figures for its three powerhouse biologic brands: Avastin, MabThera/Rituxan and Herceptin.

What’s Next? Five Things To Look Out For In July

In the month ahead, Viatris may land history-making FDA biosimilar approvals, while readers will enjoy Generics Bulletin’s usual close coverage of the quarterly financial reports.

Xbrane Data Sets Up EU And US Ranibizumab Filings

Hot on the heels of Samsung Bioepis receiving an EMA endorsement for its Byooviz version, Xbrane Biopharma has laid out plans for its own ranibizumab biosimilar, Xlucane, to be filed in both the EU and the US following positive Phase III results.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150859

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel
;